Topotecan. A review of its potential in advanced ovarian cancer.

@article{Brogden1998TopotecanAR,
  title={Topotecan. A review of its potential in advanced ovarian cancer.},
  author={Rex N. Brogden and Lynda R. Wiseman},
  journal={Drugs},
  year={1998},
  volume={56 4},
  pages={709-23}
}
The topoisomerase I inhibitor topotecan has shown antitumour activity against a variety of tumour types in vitro and in vivo. Topotecan in combination with drugs that induce DNA damage generally results in synergistic killing of tumour cells in vitro. As the activity of topotecan is related to exposure time, the drug is administered by intravenous infusion either continuously or once daily over a 30-minute period for several consecutive days. A 30-minute infusion of topotecan 1.5 mg/m2 on 5… CONTINUE READING